Interchangeability Impacting Biosimilar Uptake

EP: 1.Biologics Utilization Impacting US Health Care Spending

EP: 2.Current Landscape of Biosimilar Use in US Healthcare Space

Now Viewing

EP: 3.Interchangeability Impacting Biosimilar Uptake

EP: 4.The Impact of Payer Coverage and Reimbursement on Biosimilars

EP: 5.Navigating Biosimilar Uptake in New Patients

EP: 6.Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP: 7.Private Label Biosimilars

EP: 8.Biosimilars in the Commercial Sector

EP: 9.The Influence of Employer Preferences And Adoption of Biosimilars

EP: 10.Out of Pocket Costs Associated with Biosimilar Use

EP: 11.Unmet Needs and Future Initiatives

EP: 12.Ideal Goals for Biosimilar Utilization

EP: 13.Foreseeable Biosimilar Trends

EP: 14.Legislative Support for Biosimilars

EP: 15.Key Takeaways for Biosimilar Utilization

Video content above is prompted by the following:

• Has interchangeability impacted biosimilar adoption? If not, why?
  • What value do switching studies bring to interchangeable biosimilars?
    • Does this data matter more than the designation?
  • Do pharmacies and providers value interchangeability?
  • Have pharmacies begun acting upon interchangeability with automatic substitutions?